MSCI to Launch Investment Solutions as a Service in Collaboration with Microsoft
22.2.2021 16:00:00 EET | Business Wire | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of investment decision support tools and services, today announced the development of Investment Solutions as a Service for the global investment industry in collaboration with Microsoft Corp. The new service will allow institutional investors to use next generation technologies, advanced analytics and big data to help anticipate and address key strategic and investment challenges.
Built to align long-term technology and data trends with the immediate needs of investors, the service will combine Microsoft’s Cloud and AI technologies with MSCI’s extensive data sets, analytical models and deep expertise of the global investment industry to power next-generation investment decision making.
Investment Solutions as a Service will transform the investment process and experience, beginning with the following services launching in 2021:
- ESG Solutions as a Service
- Index Solutions as a Service
- Data Management Solutions as a Service
- Investment Analytics Solutions as a Service
The launch of these services reflects the increasing demand for technologies that offer “solutions as a service”, harness big data and provide customized experiences. The solutions are a part of the strategic alliance created between MSCI and Microsoft in 2020 to accelerate innovation in the global investment industry.
“The partnership with Microsoft underscores MSCI’s continued commitment to develop new and innovative investing solutions,” said Henry Fernandez, Chairman and CEO, MSCI. “We have combined Microsoft’s best of breed technology with our robust data and analytical capabilities and rigorous understanding of client challenges to create a suite of services to empower investors. From responding to the historic and unrivalled challenge of climate change, to harnessing the power of big data and innovative analytics, Investment Solutions as a Service is a milestone in powering the next generation of investment decision making.”
“MSCI and Microsoft share a commitment to accelerating innovation in the financial services industry,” said Scott Guthrie, Executive Vice President, Cloud + AI, Microsoft. “MSCI’s investment solutions, combined with the data and analytics capabilities of Microsoft Azure, will enable investment managers to harness intelligent insights needed to confidently navigate today’s global markets.”
Environmental, Social and Governance (ESG) Solutions as a Service
With ESG firmly established as a high-priority issue for global investors and corporations, ESG Solutions as a Service will help them better understand, analyze and interpret the investment and business risks and opportunities that climate change brings. Leveraging Microsoft’s Azure and PowerBI platforms, investors will be able to evaluate industries and companies with the world’s leading ESG analytics, and corporations will be able to understand their risk assessment when compared to their peers. The service will provide detailed insights on companies’ adaptive capacity to climate change, carbon footprint measurements, as well as exposure to physical risk, including climate-related events such as hurricanes and flooding.
Index Solutions as a Service
Index Solutions as a Service will provide investors with the opportunity to create and customize indexes, marking the first time clients will have MSCI’s index construction capabilities at their fingertips. The service is aimed at delivering an insightful and efficient experience that shortens the time from market hypothesis to new customized indexes. Built on Microsoft Azure, Index Solutions as a Service leverages the insights created through MSCI’s 50+ years of index experience. It will provide clients with a seamless, self-service experience to create, back test and analyze customized indexes; compare those indexes against established benchmarks; refine their creations through an iterative process and order them from MSCI.
Data Management Solutions as a Service & Investment Analytics Solutions as a Service
With Data Management Solutions as a Service and Investment Analytics Solutions as a Service, investors can directly discover and access in a new and dynamic manner a rich and extensive store of data sets and robust analytical capabilities from MSCI’s powerful investment solutions today. MSCI will be releasing a new Developer Portal offering APIs that seamlessly integrate with clients’ existing ecosystems. Through the Developer Portal, developers and researchers can find, select and analyze historical markets data on a range of asset classes and develop their own investment solutions that meet their specific risk and portfolio construction needs.
“The launch of MSCI’s Investment Solutions as a Service is the latest example of our continuous innovation and drive to develop cutting-edge technologies,” said Jigar Thakkar, Chief Technology Officer and Head of Engineering, MSCI. “We recognize that our clients are operating in an increasingly complex environment where the need for intelligent insights for portfolio management and risk analysis has never been more important. Our new services will provide a friction-free experience with rapid self-customization and exploration of our data sets, putting power in the hands of investors like never before.”
About MSCI
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com.
The information contained herein (the “Information”) may not be reproduced or redisseminated in whole or in part without prior written permission from MSCI. The Information may not be used to verify or correct other data, to create any derivative works, to create indexes, risk models, or analytics, or in connection with issuing, offering, sponsoring, managing or marketing any securities, portfolios, financial products or other investment vehicles. Historical data and analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information or MSCI index or other product or service constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy. Further, none of the Information or any MSCI index is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. The Information is provided “as is” and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF MSCI INC. OR ANY OF ITS SUBSIDIARIES OR ITS OR THEIR DIRECT OR INDIRECT SUPPLIERS OR ANY THIRD PARTY INVOLVED IN MAKING OR COMPILING THE INFORMATION (EACH, AN “INFORMATION PROVIDER”) MAKES ANY WARRANTIES OR REPRESENTATIONS AND, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH INFORMATION PROVIDER HEREBY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITING ANY OF THE FOREGOING AND TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL ANY OF THE INFORMATION PROVIDERS HAVE ANY LIABILITY REGARDING ANY OF THE INFORMATION FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL (INCLUDING LOST PROFITS) OR ANY OTHER DAMAGES EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited. Privacy notice: For information about how MSCI collects and uses personal data, please refer to our Privacy Notice at https://www.msci.com/privacy-pledge.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005231/en/
Contact information
Investor Inquiries
investor.relations@msci.com
Salli Schwartz, MSCI +1 212 804 5306
Media Inquiries
PR@msci.com
Sam Wang, MSCI +1 212 804 5244
Melanie Blanco, MSCI +1 212 981 1049
MSCI Global Client Service
EMEA Client Service + 44 20 7618.2222
Americas Client Service +1 888 588 4567 (toll free)
Asia Pacific Client Service + 852 2844 9333
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
